PhilipJFerroneMD
Ophthalmology • Great Neck, NYRetinal Disease
Attending, North Shore University Hosp-LI Jewish Medical Center; Assistant Professor Columbia University
Dr. Ferrone is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Northern Blvd
Ste 216
Great Neck, NY 11021Phone+1 516-466-0390Fax+1 516-829-0520
Education & Training
Duke University HospitalResidency, Ophthalmology, 1990 - 1993
Newton-Wellesley HospitalInternship, Internal Medicine, 1989 - 1990
Harvard Medical SchoolClass of 1989
Certifications & Licensure
NY State Medical License 1997 - 2026
NC State Medical License 1992 - 2024
MI State Medical License 1993 - 2009- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2007-2014
- Newsday - Top Doctors on Long Island Castle Connolly, 2008, 2010-2014
- Senior Honor Award American Society of Retinal Specialists
- Join now to see all
Clinical Trials
- Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema Start of enrollment: 2007 Mar 01
Publications & Presentations
PubMed
- 104 citationsEfficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinic...Arshad M. Khanani, Sunil S. Patel, Philip J. Ferrone, Aaron Osborne, Jayashree Sahni
JAMA Ophthalmology. 2020-09-01 - 47 citationsPlus Disease in Retinopathy of Prematurity: Improving Diagnosis by Ranking Disease Severity and Using Quantitative Image Analysis.Jayashree Kalpathy-Cramer, J. Peter Campbell, Deniz Erdogmus, Peng Tian, Dharanish Kedarisetti
Ophthalmology. 2016-11-01 - 143 citationsSubretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments TrialsAlex S. Willoughby, Gui-Shuang Ying, Cynthia A. Toth, Maureen G. Maguire, Russell Burns
Ophthalmology. 2015-09-01
Journal Articles
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationArshad M Khanani, Sunil S Patel, Philip J Ferrone, Pravin U Dugel, JAMA Ophthalmology
Authored Content
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Press Mentions
Drug Choice Makes Difference for Patients with Macular Degeneration – Consumer Health NewsDecember 7th, 2022- American Academy of Ophthalmology, Nov. 12-15November 22nd, 2021
Professional Memberships
- Fellow
- Board of Directors
- LI Ophthalmological SocietyMember
- NY State Ophthalmological SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
